The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Doxorubicin: nanotechnological overviews from bench to bedside
Open accessAbstract
Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents, used as a first-line drug in numerous types of cancer. Nevertheless, it exhibits serious adverse effects, such as lethal cardiotoxicity and dose-limiting myelosuppression. In this review, we focus on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer-drug conjugates, polymeric micelles and ligand-based DOX-loaded nanoformulations. Although some DOX-based nanoproducts are currently being used in the clinical field, it is clear that further research is necessary to achieve improvements in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Self-citationNorouzi, M., Yathindranath, V., Thliveris, J. A., Kopec, B. M., Siahaan, T. J., & Miller, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-68017-y · Cited by 292
Evolution and clinical translation of drug delivery nanomaterials
Hassan, S., Prakash, G., Bal Ozturk, A., Saghazadeh, S., Farhan Sohail, M., Seo, J., Remzi Dokmeci, M., Zhang, Y. S., & Khademhosseini, A. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.008 · Cited by 288
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Sun, D., Zhou, S., & Gao, W. (2020) · ACS Nano · doi:10.1021/acsnano.9b09713 · Cited by 263
Metadata
- Authors
- Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 22
- Issue
- 2
- Pages
- 270-281
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2555627105
- Cited by
- 362
- References
- 83
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Doxorubicin: nanotechnological overviews from bench to bedside. https://app.cochat.ai/papers/10.1016/j.drudis.2016.11.005
- The paper
- Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017). Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2016.11.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.